SAN FRANCISCO, June 13, 2017 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced the appointment of Jennifer Jarrett to its board of directors.
“We are very pleased to welcome Jen to our board of directors,” stated Matthew R. Patterson, President and Chief Executive Officer. “Jen is an accomplished life sciences industry leader who has built value through her successful roles in investment banking and industry. We will benefit enormously from Jen’s insights as we continue to advance our pipeline of product candidates and to build our business for the future.”
Ms. Jarrett serves as the Chief Financial and Business Officer of Arcus Biosciences, Inc. She served as Chief Financial Officer of Medivation, Inc. until the company’s purchase by Pfizer, Inc. in 2016. Previously, Ms. Jarrett served as Managing Director at Citigroup, where she was responsible for building and managing Citigroup’s West Coast life sciences investment banking practice. Prior to Citigroup, Ms. Jarrett was a Managing Director in Credit Suisse’s Health Care Group focused on the biotechnology sector. She earned a bachelor’s degree in economics, Cum Laude, from Dartmouth College and holds a masters of business administration from Stanford Graduate School of Business.
“I am delighted to join the Audentes board of directors having been an admirer of the company for some time,” commented Ms. Jarrett. “With its highly experienced and successful team, robust pipeline and state-of-the-art GMP manufacturing facility, Audentes has established itself as a leader in the emerging field of gene therapy. I am fortunate to be joining now as 2017 promises to be a transformational year for the company as it executes on its plans to initiate phase 1/2 studies and report preliminary data from its two lead programs by year end.”
About Audentes Therapeutics, Inc.
Audentes Therapeutics (Nasdaq: BOLD) is a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases. We have four product candidates in development, AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM), AT342 for the treatment of Crigler-Najjar Syndrome, AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT). We are a focused, experienced and passionate team committed to forging strong, global relationships with the patient, research and medical communities.
For more information regarding Audentes, please visit www.audentestx.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, the company’s 2017 development and manufacturing plans and the expected benefits of the company’s product candidates. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Although the company believes that the expectations reflected in such forward-looking statements are reasonable, the company cannot guarantee future events, results, actions, levels of activity, performance or achievements, and the timing and results of biotechnology development and potential regulatory approval is inherently uncertain. Forward-looking statements are subject to risks and uncertainties that may cause the company’s actual activities or results to differ significantly from those expressed in any forward-looking statement, including risks and uncertainties related to the company’s ability to advance its product candidates, obtain regulatory approval of and ultimately commercial its product candidates, the timing and results of preclinical and clinical trials, the company’s ability to fund development activities and achieve development goals, the company’s ability to protect intellectual property and other risks and uncertainties described under the heading “Risk Factors” in documents the company files from time to time with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release, and the company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof.
Contacts:
Investor Contact:
Thomas Soloway, CFO
415.818.1040
ir@audentestx.com
Media Contact:
Paul Laland
415.519.6610
media@audentestx.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/audentes-therapeutics-appoints-jennifer-jarrett-to-board-of-directors-300472816.html
SOURCE Audentes Therapeutics, Inc.
